Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00170937 · ClinicalTrials.gov registry record · Phase 4
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 507
- Enrollment target
NCT00170937 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 507 participants.
The verdict
NCT00170937, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 507 participants
- Enrollment target
Study Summary
The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar. Three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for the development of diabetes and cardiovascular diseases. The purpose of this study is to determine whether two common drugs to lower blood pressure, whether used separately or in combination, have different effects on blood sugar levels in patients diagnosed with the metabolic syndrome.
Interventions
- DRUG valsartan plus hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2004-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00170937
The ClinicalTrials.gov registry entry for NCT00170937 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valsartan plus hydrochlorothiazide is the first listed.
NCT00170937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00170937 about?
NCT00170937 is a clinical study titled "A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome". The metabolic syndrome is a classification for patients with a constellation of risk factors which may include abdominal obesity, hypertension, elevated blood lipids and sugar. Three or more of these factors together constitute the metabolic syndrome and place these patients at a greater risk for th...
What is the current status of trial NCT00170937?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 507 participants. The study started on 2004-11.
What interventions are being tested in trial NCT00170937?
The interventions under investigation include: valsartan plus hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00170937?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.